ArticleMolecular immunology2012

Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting.

Josef Singer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.